Abridge AI Hits $5.3B Valuation as Andreessen Horowitz Leads $300M Round
- Abridge AI is raising $300M in a funding round led by Andreessen Horowitz, valuing the healthcare AI startup at $5.3 billion.
- The company’s rapid growth reflects investor confidence in AI-driven medical documentation as a scalable solution to healthcare inefficiencies.
Pittsburgh-based health tech startup Abridge AI Inc. is raising $300 million in a new funding round, boosting its valuation to $5.3 billion. The round is being led by venture capital giant Andreessen Horowitz (a16z), with Khosla Ventures also participating, according to sources familiar with the matter.
The company, founded in 2018, builds artificial intelligence tools that transcribe and summarize medical conversations. Its software captures doctor-patient discussions and generates clinical notes in real time, reducing the burden of documentation on physicians.
This new round marks a sharp rise in Abridge’s valuation. In February 2025, the company raised $250 million at a $2.75 billion valuation. The latest investment nearly doubles that figure, signaling strong investor interest in AI applications within healthcare.
Abridge’s rapid growth reflects the broader trend of artificial intelligence being applied to high-impact sectors. In clinical settings, where time and accuracy are critical, automating note-taking offers clear advantages.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
The Founder and CEO of the company, Shiv Rao, said earlier
“Abridge unburdens clinicians from the clerical work that crushes their souls, so they can focus on the person in front of them,”
While the details of the funding round remain private, the sharp valuation increase places Abridge among the top emerging players in the AI-driven transformation of healthcare.
Edited by Harshajit Sarmah
More in Funding
